Archive | Artificial Intelligence (AI) RSS feed for this section

Hot AI Mandate: Canada-based Family Office Looking for Big-data or AI-related Opportunities in Healthcare

11 May

A single family office founded in 2009 and based in Toronto is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot AI Mandate: US-based VC Invests in Early-stage AI-enabled Platforms in Healthtech

11 May

Founded in 2006, a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management will close their fourth fund in 2021. The firm invests in early-stage companies (Seed/Series A) developing innovative new medical technologies, biotechnologies, and digitally-enabled healthcare services. The firm generally invests $4-8 million of equity capital per round and up to $10-20 million over the investment life. The firm is actively investing and will make 3-5 investments in 2021.The firm invests nationally and has offices in Austin, TX, and Boston, MA.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics, and Healthcare IT products. For medical devices and therapeutics, the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. In HealthTech, the firm is interested in AI-enabled clinical/diagnostic/workflow platforms but will also consider other companies that fall into the broader Healthcare IT space as well, including mobile health companies developing consumer-facing apps. They will consider companies with proprietary platform technologies as well as single/multiple asset companies.

As an early-stage investor, the firm invests almost exclusively in pre-revenue companies, with significant ownership opportunities. They look for experienced management teams, help build the team, and require a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Stories for a New Age

6 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

When LifeBio Founder and CEO, Beth Sanders started telling stories, she knew how influential they could be. Today, patients and healthcare providers are using LifeBio’s storytelling platform to connect, decrease loneliness, and promote better care and overall wellness.

LifeBio was a winner at the March Innovator’s Pitch Challenge at Longevity, Health & Innovation (now RESI Longevity). Registration for RESI Longevity (September 16-17) is now open at super early bird rates until July 23, and applications for the next Innovator’s Pitch Challenge are open!

Listen to our conversation with Beth on the origin and mission of LifeBio, and how stories are having a strong impact on today’s seniors and the healthcare system.

Introducing RESI AI and RESI Longevity

22 Apr

By Caitlin Dolegowski, Marketing Specialist, LSN

Caiti

Life Science Nation (LSN) renames its two newest conferences under the Redefining Early Stage Investments (RESI) banner. This conference series has provided early-stage life science entrepreneurs a space dedicated to their fundraising efforts through connecting them with partners and capital that are a fit for their product and stage of development. Through the years, LSN has worked with thousands of executives in their search for partnerships, and the secret has always been that it all comes down to finding that right fit. In order to help target these elusive matches, LSN spun two sister conferences, 4D Meets AI and Longevity, Health and Innovation, now RESI AI and RESI Longevity respectively, out of the RESI conference series, designed to further narrow down the early-stage life science players, based on technology and indication.

4D Meets AI has focused on connecting entrepreneurs using AI technology to advance drugs, devices, diagnostics, and digital health (4Ds) with investors and partners actively seeking AI applications in their themes and portfolios. Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, is a space for fundraising executives targeting diseases that disproportionately affect aging populations to connect with capital and resources specifically in age-tech.

These two conferences are designed to create a more intimate atmosphere within the RESI partnering ecosystem. Each invites a unique attendee, yet both are a digital partnering conferences advancing the mission of the RESI series – to connect technology in life science and health care with well-fitting capital and channel partners – which is why they return this fall as RESI AI and RESI Longevity.

RESI Longevity and RESI AI both take place September 16-17 as two-day digital partnering conferences. Each will feature their own unique lineups of Investor Panels, Educational Workshops, Innovator’s Pitch Challenges and Premier Partnering Platforms. Learn more about each conference and sign up by July 23 to save $100 on super early bird prices!

Congratulations to the 4D Meets AI Innovator’s Pitch Challenge Winners!

25 Mar

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s 4D Meets AI partnering conference successfully concluded last Friday, March 19. Over the two-day event, LSN featured seven exceptional startup companies at the intersection of AI and life science through the Innovator’s Pitch Challenge (IPC).

Each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials, and they participated in a live Q&A session with a panel of investor pitch judges. Conference attendees were able to visit these landing pages or join the live Q&A sessions, and they were encouraged to vote for their favorite IPC companies before the end of the conference.

Many thanks to all the IPC companies for their hard work promoting their technologies and to the pitch judges who supported each session with their feedback. Each company was judged on their supporting materials, as well as their live pitch and Q&A. Congratulations to Huma.AI and Thrive Bioscience for winning their sessions!

Huma.ai is a venture-backed healthcare AI company. It’s ML-enabled, questions and answers-driven knowledge automation platform turns domain experts into their own data scientists so that they can make real-time decisions driven by data. According to its customers, Huma.ai has cracked the Holy Grail.

Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.

If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the Digital RESI IPC taking place June 8-10. Applications close May 14!

This image has an empty alt attribute; its file name is digital-june-2021-banner-1100.png

Keep the Conversations Going

18 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Healthtech Partnering Week is off to the races! Digital RESI March has wrapped up with 1,000+ meetings in 3 days and leads into a triple-threat partnering experience consisting of 4D Meets AI, Access China Spring Forum (free), and Longevity, Health & Innovation taking place consecutively March 18-19.

It’s not too late to sign up and get involved in any of these three events! To learn more, visit the Healthtech Partnering Week website. Each conference offers unique opportunities suited for specific technology assets and market solutions. We hope you’ll join us and round out your RESI partnering with the full Healthtech Partnering Week experience!





Hot Mandate: Investment Arm of Hospital System Interested In Novel Applications in Digital Health

15 Mar

A investment arm of a non-profit hospital system manages a $15M fund and usually writes checks in the $1 million range. The firm will participate mostly in Series A and B rounds but is open to considering earlier stage, non-revenue generating companies with highly disruptive technologies. Currently, the firm is focused only on USA-based investment opportunities.

The firm is seeking digital health companies with technologies that can provide significant value to their hospital system. The firm is most interested in those that address their key organization priorities, which include (1) virtualization of care (i.e. telehealth), (2) operational efficiency, (3) patient and clinician experience of care. The organization is also interested in novel applications of technologies such as AI that may not impact healthcare in the short term, but may have disruptive potentials in the future. The organization is not interested in therapeutics, medical devices, or diagnostics companies.

The firm is looking to work with companies with experienced management teams. The firm does not act as a lead investor and only seeks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

← Older Entries
Newer Entries →